Abstract:Halogenated tyrosine/phenylalanine derivatives have been developed for use in tumor imaging and targeted alpha therapy. 3-Fluoro-α-methyl-l-tyrosine (FAMT), targeting amino acid transporter LAT1 (SLC7A5), is a cancer-specific positron emission tomography probe that exhibits high renal accumulation, which is supposed to be mediated by organic anion transporter OAT1 (SLC22A6). In the present study, we investigated the structural requirements of FAMT essential for interaction with OAT1. OAT1 transported FAMT with a K m of 171.9 μM. In structure-activity relationship analyses, removal of either the 3-halogen or 4-hydroxyl group from FAMT or its structural analog 3-iodo-α-methyl-l-tyrosine greatly decreased the interaction with OAT1, reducing the [14C]p-aminohippurate uptake inhibition and the efflux induction. By contrast, the α-methyl group, which is essential for LAT1 specificity, contributed to a lesser degree. In fluorinated tyrosine derivatives, fluorine at any position was accepted by OAT1 when there was a hydroxyl group at the ortho-position, whereas ortho-fluorine was less interactive when a hydroxyl group was at meta- or para-positions. The replacement of the ortho-fluorine with a bulky iodine atom greatly increased the interaction. In in vivo studies, probenecid decreased the renal accumulation (P < 0.001) and urinary excretion (P = 0.0012) of FAMT, whereas the plasma concentration was increased, suggesting the involvement of OAT1-mediated transepithelial organic anion excretion. LAT1-specific 2-fluoro-α-methyltyrosine, which had lower affinity for OAT1, exhibited lower renal accumulation (P = 0.0142) and higher tumor uptake (P = 0.0192) compared with FAMT. These results would provide a basis to design tumor-specific compounds that can avoid renal accumulation for tumor imaging and targeted alpha therapy. SIGNIFICANCE STATEMENT: We revealed the structural characteristics of halogenated tyrosine derivatives essential for interaction with the organic anion transporter responsible for their renal accumulation. We have confirmed that such interactions are important for renal handling and tumor uptake. The critical contribution of hydroxyl and halogen groups and their positions as well as the role of α-methyl group found in the present study may facilitate the development of tumor-specific compounds while avoiding renal accumulation for use in tumor imaging and targeted alpha therapy.

Structural Features Affecting the Interactions and Transportability of LAT1-Targeted Phenylalanine Drug Conjugates

L-Type amino acid transporter 1 as a target for drug delivery

The Multifaceted Role of L-Type Amino Acid Transporter 1 at the Blood-Brain Barrier: Structural Implications and Therapeutic Potential

Structure–activity characteristics of phenylalanine analogs selectively transported by L-type amino acid transporter 1 (LAT1)

Insights into the Structure, Function, and Ligand Discovery of the Large Neutral Amino Acid Transporter 1, LAT1

Mechanism of Substrate Transport and Inhibition of the Human LAT1-4F2hc Amino Acid Transporter

Structure of the human LAT1–4F2hc heteromeric amino acid transporter complex

The L-type amino acid transporter 1 enhances drug delivery to the mouse pancreatic beta cell line (MIN6)

Comprehensive Characterization of LAT1 Cholesterol-Binding Sites

Interaction of Halogenated Tyrosine/Phenylalanine Derivatives with Organic Anion Transporter 1 in the Renal Handling of Tumor Imaging Probes

L-type amino acid transporter 1 (LAT1)- targeting nanoparticles for antisense oligonucleotide delivery to the central nervous system

Exploring Amino Acid Transporters as Therapeutic Targets for Cancer: An Examination of Inhibitor Structures, Selectivity Issues, and Discovery Approaches

Grafted Hyaluronic Acid N-acetyl-l-methionine for Targeting of LAT1 Receptor: In-silico, Synthesis and Microscale Thermophoresis Studies.

Targeted efflux transporter inhibitors - A solution to improve poor cellular accumulation of anti-cancer agents

Development of a cell-based screening method for compounds that inhibit or are transported by large neutral amino acid transporter 1, a key transporter at the blood–brain barrier

LAT1 transporter as a target for breast cancer diagnosis and therapy

The Complete Assembly of Human LAT1-4F2hc Complex Provides Insights into Its Regulation, Function and Localisation

Development of LAT1-Selective Nuclear Medicine Therapeutics Using Astatine-211

L-amino acid transporter-1 and boronophenylalanine-based boron neutron capture therapy of human brain tumors

L-type Amino Acid Transporter 1 as a Therapeutic Target in Pancreatic Cancer

Conserved Lysine in transmembrane helix 5 is key for the inner gating of the LAT transporter BasC